Neuronetics (NASDAQ:STIM) Stock Price Down 2.2% – Here’s What Happened

Posted by Stanley Muller on Oct 28th, 2026

Neuronetics, Inc. (NASDAQ:STIM – Get Free Report)’s stock price traded down 2.2% during mid-day trading on Tuesday. The company traded as low as $2.18 and last traded at $2.19. 278,261 shares traded hands during mid-day trading, The stock had previously closed at $2.24.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Citigroup restated a “market outperform” rating on shares of Neuronetics in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research report on Monday, September 14th. BTIG Research reiterated a “buy” rating and issued a $6.00 price objective on shares of Neuronetics in a research note on Thursday, September 17th. Wall Street Zen upgraded Neuronetics from a “sell” rating to a “hold” rating in a research note on Sunday, July 12th. Finally, B. Riley Financial began coverage on Neuronetics in a research report on Friday, September 11th. They set a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Neuronetics has an average rating of “Moderate Buy” and a consensus price target of $4.67.

View Our Latest Analysis on STIM

Neuronetics Price Performance

The stock’s 50-day simple moving average is $2.57 and its 200 day simple moving average is $1.87.

Neuronetics (NASDAQ:STIM – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.07. The firm had revenue of $41.57 million during the quarter, compared to analyst estimates of $40.17 million. As a group, equities research analysts anticipate that Neuronetics, Inc. will post -0.33 earnings per share for the current year.

Insider Buying and Selling

In other Neuronetics news, major shareholder Jorey Chernett purchased 14,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $3.16 per share, for a total transaction of $44,240.00. Following the completion of the purchase, the insider directly owned 10,602,988 shares in the company, valued at approximately $33,505,442.08. This represents a 0.13% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in STIM. Fielder Capital Group LLC purchased a new position in shares of Neuronetics in the 2nd quarter valued at about $30,000. State of Wyoming acquired a new stake in shares of Neuronetics during the 2nd quarter worth about $31,000. IMC Chicago LLC acquired a new stake in shares of Neuronetics during the 1st quarter worth about $40,000. David J Yvars Group raised its position in shares of Neuronetics by 35.7% during the 2nd quarter. David J Yvars Group now owns 27,550 shares of the company’s stock worth $36,000 after acquiring an additional 7,250 shares in the last quarter. Finally, T3 Companies LLC purchased a new stake in Neuronetics during the third quarter worth approximately $88,000. 53.59% of the stock is owned by institutional investors and hedge funds.

Neuronetics Company Profile

(Get Free Report)

Neuronetics, Inc is a medical technology company that develops and commercializes noninvasive treatments for psychiatric and neurological disorders. Its primary product is NeuroStar TMS Therapy, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain associated with mood regulation.

NeuroStar TMS Therapy is cleared by the U.S. Food and Drug Administration for treating major depressive disorder in adults and adolescents, obsessive-compulsive disorder, and depression with anxious distress.